PH12017502322B1 - Therapeutic agent for fibrosis - Google Patents
Therapeutic agent for fibrosisInfo
- Publication number
- PH12017502322B1 PH12017502322B1 PH1/2017/502322A PH12017502322A PH12017502322B1 PH 12017502322 B1 PH12017502322 B1 PH 12017502322B1 PH 12017502322 A PH12017502322 A PH 12017502322A PH 12017502322 B1 PH12017502322 B1 PH 12017502322B1
- Authority
- PH
- Philippines
- Prior art keywords
- fibrosis
- therapeutic agent
- amino
- thioxomethyl
- quinolinecarboxamide
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 4
- 230000004761 fibrosis Effects 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12017502322A1 PH12017502322A1 (en) | 2018-06-25 |
| PH12017502322B1 true PH12017502322B1 (en) | 2023-08-30 |
Family
ID=57585165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2017/502322A PH12017502322B1 (en) | 2015-06-25 | 2016-06-24 | Therapeutic agent for fibrosis |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (enExample) |
| EP (2) | EP3315131B1 (enExample) |
| JP (3) | JP6974167B2 (enExample) |
| KR (1) | KR102647942B1 (enExample) |
| CN (2) | CN107708697B (enExample) |
| AU (1) | AU2016284531B2 (enExample) |
| BR (1) | BR112017028137B1 (enExample) |
| CA (1) | CA2990791A1 (enExample) |
| DK (1) | DK3315131T3 (enExample) |
| ES (1) | ES2928684T3 (enExample) |
| HU (1) | HUE060732T2 (enExample) |
| MA (1) | MA42266A (enExample) |
| MX (2) | MX381792B (enExample) |
| MY (1) | MY191219A (enExample) |
| PH (1) | PH12017502322B1 (enExample) |
| PL (1) | PL3315131T3 (enExample) |
| PT (1) | PT3315131T (enExample) |
| RU (1) | RU2729630C2 (enExample) |
| SG (2) | SG11201709260TA (enExample) |
| WO (1) | WO2016208744A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| KR102323255B1 (ko) | 2017-02-15 | 2021-11-08 | 다이호야쿠힌고교 가부시키가이샤 | 의약 조성물 |
| AU2018329881B2 (en) | 2017-09-08 | 2021-12-02 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and antitumor effect potentiator |
| EP3854395A4 (en) | 2018-09-18 | 2022-06-15 | Taiho Pharmaceutical Co., Ltd. | POLYTHERAPY COMBINING AN ACYLTHIOUREA COMPOUND AND ABIRATERONE |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4094814B2 (ja) | 1998-04-28 | 2008-06-04 | 敏一 中村 | 血管新生抑制剤 |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| EP1896461A2 (en) | 2005-06-30 | 2008-03-12 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| ZA200804681B (en) * | 2005-11-30 | 2009-11-25 | Vertex Pharma Inc | Inhibitors of C-Met and uses thereof |
| EP2114898A2 (en) | 2007-02-16 | 2009-11-11 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| MX2010004491A (es) | 2007-10-25 | 2010-06-21 | Astrazeneca Ab | Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares. |
| TWI438193B (zh) * | 2008-04-10 | 2014-05-21 | Taiho Pharmaceutical Co Ltd | 醯基硫脲化合物或其鹽、及其用途 |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| ES2608329T3 (es) | 2010-02-03 | 2017-04-07 | Incyte Holdings Corporation | Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
-
2016
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY191219A (en) | Therapeutic agent for fibrosis | |
| IL276169A (en) | Peptide YY pharmacological formulations, compositions and methods | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| HK1249893A1 (zh) | 氘代vx-661 | |
| EP3638349A4 (en) | DEVICES FOR ADMINISTERING AN ACTIVE SUBSTANCE AND METHOD OF USING THEREOF | |
| WO2016131067A3 (en) | Pharmaceutical compositions comprising meloxicam | |
| MY190855A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| EP4527467A3 (en) | Pharmaceutical formulations | |
| SG11201808607SA (en) | Medicine obtained by combining fxr agonist and arb | |
| PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| IN2014MU01042A (enExample) | ||
| EP4342461A3 (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| MY183068A (en) | Pharmaceutical formulation comprising antibody | |
| EP3849992A4 (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
| CA3011003A1 (en) | Bacterial ghosts for the treatment of cancer | |
| MX2017010277A (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
| WO2014145126A3 (en) | Methods of treating dyskinesia and related disorders | |
| MX356789B (es) | Composición de difenidol de liberación prolongada. | |
| PH12018500817B1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| HK1245131A1 (zh) | 用於治疗炎症性疾病的包含十六酰胺乙醇pea和番茄红素的组合物 | |
| WO2015100370A3 (en) | Sustained release depot formulations of therapeutic proteins, and uses thereof | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
| PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis |